Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tetanus toxoid and diphtheria toxoid are purified, chemically (commonly formaldehyde) or genetically inactivated forms of the highly potent tetanus and diphtheria bacterial protein toxins. When used as vaccines, these toxoids are strongly immunogenic but non-toxic, stimulating the host's immune system to produce neutralizing antibodies without the risk of toxin-mediated disease. Their use has dramatically reduced the incidence of tetanus and diphtheria worldwide[6][4]. Neither toxoid is a pharmacological target (receptor, enzyme, transporter), but both serve as antigens in vaccines and targets for the adaptive immune system.
Induces adaptive immune response generating neutralizing antibodies; these antibodies then neutralize the respective native toxins if encountered, preventing disease.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tetanus toxoid and Diphtheria toxoid (TT, DT).